Microglial TRPV1 in epilepsy: Is it druggable for new antiepileptic treatment?

Epilepsy is one of the most common neurological diseases worldwide with a high prevalence and unknown pathogenesis. Further, its control challenging. It generally accepted that an imbalance between excitatory inhibitory properties central nervous system (CNS) leads to large number abnormally synchronized neuronal discharges in brain. Transient receptor potential vanilloid protein type 1 (TRPV1) non-selective cation channel contributes regulation influences excitability system. This includes release neurotransmitters, action generation due alterations ion channels, synaptic transmission, changes glial cells. There abundant evidence TRPV1 widely expressed (including microglia) involved development epilepsy through neuroinflammation. In conclusion, microglial participates neuroinflammatory reactions functions as proinflammatory mediator. presents novel treatment approach regulate seizures brought on by